Articles

Three peptides have large randomised weight-loss trials behind them. Most compounds sold as weight-loss peptides have little or nothing. Here is the split.

IGF-1 LR3 has no published human trials. What the mecasermin data shows, why progress photos are not evidence, and the IGF-1 cancer association explained.

Every MOTS-c dose circulating online traces back to rodent studies. What was administered, to what, and why no human dosing protocol exists.

Sermorelin under FDA 503A compounding rules: what the regulatory record says, what changed, and what it means for legal access.

The sauna and heart-health findings come largely from one Finnish cohort. What it found, what the physiology supports, and why no trial has confirmed it.

Insulin resistance tracks with cardiovascular disease well before diabetes appears. What the cohort data show, what genetics add, and where the causal claim stops.

Creatine is well established for muscle. For the brain the evidence is thinner and conditional. What the trials show, in whom, and under what stress.

What randomized trials in adults over 50 show about resistance training for strength, muscle, bone and daily function, and what they do not establish.

Both short and long sleep track with higher mortality. What that U-shaped curve establishes, what it cannot, and what follows for how you sleep.

We searched PubMed and Europe PMC for human trials of injectable GHK-Cu. What exists, what the topical studies show, and why they do not transfer.

Five randomised semaglutide trials, what each one measured, how much weight participants lost, and the questions none of them answer.

BPC-157's healing claims rest almost entirely on rodent studies. Here's what three decades of research establishes, and where it stops cold.

A close read of the 2015 GHK-Cu gene-expression paper: what the Connectivity Map data shows, and why the systemic-modulator claim outruns the evidence.

A source-grounded look at topical GHK-Cu: the human trials, the proposed mechanisms, published dosing, and where the copper peptide falls short of the hype.

A concise, evidence-graded primer on tesamorelin: origin, approved use, research doses, and what the trials show versus what's assumed.

Collagen peptides have RCTs behind them. BPC-157 and TB-500 don't. A source-grounded look at what 'natural peptide' evidence means.

A source-grounded look at GHK-Cu's human trial data, proposed mechanisms, published dosing, and where it stands versus other peptides.

What SURMOUNT and SURPASS trials actually recorded on tirzepatide dosing, timelines, and outcomes, and where the published data stops.

A research-oriented primer on GHK-Cu: what it is, what the literature supports, where the evidence is thin, and what to read next.

A deep-dive into GHK-Cu peptide: what human trials, animal studies, and cell-line work support, where the evidence is weak, and what researchers used for dosing.

A deep-dive into CJC-1295 versus sermorelin, tesamorelin, and ipamorelin, what clinical trials show, where the gaps are, and which peptide has the stronger case.

GHK-Cu and Matrixyl both claim to rebuild collagen. Here's how their trial data, safety records, and practical use cases actually compare.

A deep-dive into BPC-157's real evidence base: what animal studies show, what human data exists, mechanisms, dosing protocols, and where the science falls short.

A source-grounded look at TB-500's human and animal evidence, mechanism, published dosing, and how it stacks up against BPC-157.

A source-grounded deep-dive into BPC-157 results across animal and human data, covering mechanisms, published dosing protocols, side effects, and what's still unknown.

BPC-157 sits in a legal grey zone. Here is what the FDA, WADA, and international regulators have said, and what that means for research use.

A research-oriented primer on BPC-157: what it is, what the preclinical literature shows, how researchers dose it, and where the evidence ends.

A critical breakdown of BPC-157 side effect data, from preclinical findings to the near-total absence of controlled human safety trials.

TB-500 and BPC-157 compared on efficacy, safety, and practical use. See which peptide has stronger evidence for tissue repair and recovery decisions.

The claim that BPC-157 is orally bioavailable circulates widely in peptide forums. Here is what the actual literature supports and where the myth breaks down.

A deep-dive into TB-500's evidence base for tendon recovery, covering preclinical data, proposed mechanisms, published dosing protocols, and where it stands vs. alternatives.